The consolidated net profit attributable to shareholders of Mankind Pharma Limited increased by 29.6% compared to the previous year, reaching ₹568.06 crore for the quarter ending June 30, 2026. The profit growth was driven by operating expenses growing slower than revenue, and a decrease in financial costs.
First Quarter Financial Results
Revenue from operations grew by 12.9%, amounting to ₹4,030.59 crore compared to ₹3,570.35 crore in the same quarter last year. Other income decreased to ₹45 crore from ₹79.88 crore, leading to total income exceeding the figure by 11.7% and reaching ₹4,075.59 crore.
The group stated that its core business is focused on the manufacturing and marketing of pharmaceutical and medical products, and it has one reporting segment—pharmaceuticals. The report did not disclose growth metrics by therapeutic area, geography, or volume for this quarter.
Profit Growth Factors
Total expenses rose by 6.3%, reaching ₹3,310.08 crore from ₹3,112.91 crore. Meanwhile, financial costs decreased by 35.6%, amounting to ₹109.98 crore. Employee welfare expenses increased to ₹913.50 crore from ₹783.41 crore, and other expenses rose to ₹962.63 crore from ₹886.58 crore.
Profit before tax increased by 42.4%, reaching ₹769.45 crore from ₹540.49 crore. There were no exceptional items in the current quarter. However, the income tax more than doubled, rising by 103.8% to ₹195.36 crore, which moderated the net profit growth relative to the profit before tax growth.
The net profit margin, calculated based on profit attributable to the parent company's owners and operating revenue, expanded by approximately 182 basis points, reaching 14.1% from 12.3%. Earnings per share grew by 29.6%, reaching ₹13.76 from ₹10.62.
Taxation and Deal Matters
The company reported that assessment decisions related to disputes initiated after the previous tax audit include adjustments totaling ₹1,908.66 crore. These amounts included ₹1,608.60 crore in disallowed expenses, ₹257.13 crore in partial disallowances claimed under sections 80IC and 80IE, and ₹42.93 crore under other heads.
Mankind Pharma and some of its associated group entities have appealed these decisions to the Commissioner of Income Tax (Appeals). Management stated that the demands are unfounded and expects them not to have a material impact on consolidated results or operations. Joint statutory auditors noted this issue but issued an unqualified opinion on the quarterly results.
Furthermore, the board approved a corporate guarantee of up to ₹150 crore in favor of banks for credit lines that may be obtained or have already been obtained by Bharat Serums and Vaccines Limited, a wholly-owned subsidiary. This guarantee will be treated as a contingent liability within the availed financing amount.
The board also approved the sale of Mankind Pharma's entire stake in Broadway Hospitality Services Private Limited for ₹49 crore in cash, subject to closing adjustments. The share purchase agreement was signed on July 27, 2026.


